NCT00143702已完成2 期
Randomized, Open-Label Study of Continued Stavudine Versus Abacavir Substitution With or Without Riboflavin and Thiamine Supplementation in HIV-Infected Patients Who Have Elevated Venous Lactic Acid While on Stavudine-Based Therapy (DAVE)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 3
- 主要终点
- Proportion of patients per arm with random venous lactic acid (RVLA) below or equal to 2.1 mmol/L* at 16 weeks. (* Confirmed by a second determination 7-14 days later.)
研究概览
简要总结
The purpose of this study is to determine the best way to treat people on d4T (stavudine) with high levels of lactic acid. Switching from d4T to abacavir will be assessed. Adding riboflavin and thiamine will also be assessed.
Participants will be randomly assigned to one of four groups:
- Group 1 participants will continue to take d4T as part of their antiretroviral (ARV) regimen, and will be given the vitamin supplements
- Group 2 will continue to take d4T without vitamin supplements
- Group 3 will switch from d4T to abacavir and receive the vitamins
- Group 4 will switch from d4T to abacavir without vitamin supplements.
The study plans to involve eighty participants from Canada and Argentina for a treatment period of 16 weeks and a follow-up visit at week 24.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be HIV-positive
- •Be 18 years of age or older
- •Have a viral load equal to or below 50 copies/mL
- •Have been on a d4T-containing multiple drug regimen (at least three agents in total) for at least six months
- •Have been on a stable ARV regimen for the three months prior to enrollment
- •Have a venous lactic acid measurement above 2.1 mmol/L within the three months prior to enrollment and two consecutive measurements above 2.1 but lower than 6.0 within a two-week period of screening
- •Be willing to discontinue L-carnitine and/or coenzyme Q10
- •Be willing and able to provide informed consent
排除标准
- •Pregnancy or breastfeeding
- •Venous lactic acid equal to or above 6.0 mmol/L
- •Previous exposure to abacavir
- •Virologic rebound while on a previous regimen consisting of dual or triple nucleoside reverse transcriptase inhibitors (NRTIs)
- •Use of hydroxyurea within the three months prior to enrollment
- •Use of metformin
- •Any acute cardiopulmonary illness or infection
- •New AIDS-defining illness diagnosed within four weeks of enrollment
- •Riboflavin or thiamine supplementation above 20 mg/day within 30 days prior to enrollment
结局指标
主要结局
Proportion of patients per arm with random venous lactic acid (RVLA) below or equal to 2.1 mmol/L* at 16 weeks. (* Confirmed by a second determination 7-14 days later.)
时间窗: 16 weeks
次要结局
- Rate of decline of RVLA levels
- Absolute level of change of RVLA levels using baseline values as a covariant
- Proportion of patients improving/normalizing exercise testing mitochondrial dysfunction pattern
- Time to event: time to normalize venous lactic acid
- Time to event: premature therapy discontinuation, viral load rebound, and progression to a new AIDS defining illness or death
- Proportion of patients with at least three consecutive HIV-1 RNA determinations equal to or below 50 copies/mL during the 16 week follow-up period on an intention to treat basis(16 weeks)
- Change in absolute CD4 from baseline
- Absolute CD4/CD8 counts
- Incidence of grade III and greater adverse drug effects
- Metabolic laboratory assessments (anion gap, lipid and hepatic profile, and hematology)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV PatientsHIV InfectionsNCT00007202National Institute of Allergy and Infectious Diseases (NIAID)55
已完成
3 期
A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia ComplexAIDS Dementia ComplexHIV InfectionsNCT00002246Bristol-Myers Squibb20
已完成
3 期
Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)AIDSHIV InfectionsNCT00116298Bristol-Myers Squibb900
已完成
2 期
Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected ChildrenHIV InfectionsNCT00000851National Institute of Allergy and Infectious Diseases (NIAID)198
已完成
2 期
A Study of Viracept in HIV-Positive WomenHIV InfectionsNCT00002171Agouron Pharmaceuticals